A personalized platform identifies trametinib plus zoledronate for a patient with KRAS-mutant metastatic colorectal cancer

Colorectal cancer remains a leading source of cancer mortality worldwide. Initial response is often followed by emergent resistance that is poorly responsive to targeted therapies, reflecting currently undruggable cancer drivers such as KRAS and overall genomic complexity. Here, we report a novel ap...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
الحاوية / القاعدة:Sci Adv
المؤلفون الرئيسيون: Bangi, Erdem, Ang, Celina, Smibert, Peter, Uzilov, Andrew V., Teague, Alexander G., Antipin, Yevgeniy, Chen, Rong, Hecht, Chana, Gruszczynski, Nelson, Yon, Wesley J., Malyshev, Denis, Laspina, Denise, Selkridge, Isaiah, Rainey, Hope, Moe, Aye S., Lau, Chun Yee, Taik, Patricia, Wilck, Eric, Bhardwaj, Aarti, Sung, Max, Kim, Sara, Yum, Kendra, Sebra, Robert, Donovan, Michael, Misiukiewicz, Krzysztof, Schadt, Eric E., Posner, Marshall R., Cagan, Ross L.
التنسيق: Artigo
اللغة:Inglês
منشور في: American Association for the Advancement of Science 2019
الموضوعات:
Research Articles
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC6531007/
https://ncbi.nlm.nih.gov/pubmed/31131321
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/sciadv.aav6528
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة